Pathogenic Old World arenaviruses inhibit TLR2/Mal-dependent proinflammatory cytokines in vitro

Lymphocytic choriomeningitis virus (LCMV), the prototype arenavirus, and Lassa virus (LASV), the causative agent of Lassa fever (LF), have extensive strain diversity and significant variations in pathogenicity for humans and experimental animals. The WE strain of LCMV (LCMV-WE), but not the Armstron...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of virology Jg. 86; H. 13; S. 7216
Hauptverfasser: Hayes, Melissa W, Carrion, Jr, Ricardo, Nunneley, Jerritt, Medvedev, Andrei E, Salvato, Maria S, Lukashevich, Igor S
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 01.07.2012
Schlagworte:
ISSN:1098-5514, 1098-5514
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Lymphocytic choriomeningitis virus (LCMV), the prototype arenavirus, and Lassa virus (LASV), the causative agent of Lassa fever (LF), have extensive strain diversity and significant variations in pathogenicity for humans and experimental animals. The WE strain of LCMV (LCMV-WE), but not the Armstrong (Arm) strain, induces a fatal LF-like disease in rhesus macaques. We also demonstrated that LASV infection of human macrophages and endothelial cells resulted in reduced levels of proinflammatory cytokines. Here we have shown that cells infected with LASV or with LCMV-WE suppressed Toll-like receptor 2 (TLR2)-dependent proinflammatory cytokine responses. The persisting isolate LCMV clone 13 (CL13) also failed to stimulate interleukin-6 (IL-6) in macrophages. In contrast, nonpathogenic Mopeia virus, which is a genetic relative of LASV and LCMV-Arm induced robust responses that were TLR2/Mal dependent, required virus replication, and were enhanced by CD14. Superinfection experiments demonstrated that the WE strain of LCMV inhibited the Arm-mediated IL-8 response during the early stage of infection. In cells transfected with the NF-κB-luciferase reporter, infection with LCMV-Arm resulted in the induction of NF-κB, but cells infected with LCMV-WE and CL13 did not. These results suggest that pathogenic arenaviruses suppress NF-κB-mediated proinflammatory cytokine responses in infected cells.
AbstractList Lymphocytic choriomeningitis virus (LCMV), the prototype arenavirus, and Lassa virus (LASV), the causative agent of Lassa fever (LF), have extensive strain diversity and significant variations in pathogenicity for humans and experimental animals. The WE strain of LCMV (LCMV-WE), but not the Armstrong (Arm) strain, induces a fatal LF-like disease in rhesus macaques. We also demonstrated that LASV infection of human macrophages and endothelial cells resulted in reduced levels of proinflammatory cytokines. Here we have shown that cells infected with LASV or with LCMV-WE suppressed Toll-like receptor 2 (TLR2)-dependent proinflammatory cytokine responses. The persisting isolate LCMV clone 13 (CL13) also failed to stimulate interleukin-6 (IL-6) in macrophages. In contrast, nonpathogenic Mopeia virus, which is a genetic relative of LASV and LCMV-Arm induced robust responses that were TLR2/Mal dependent, required virus replication, and were enhanced by CD14. Superinfection experiments demonstrated that the WE strain of LCMV inhibited the Arm-mediated IL-8 response during the early stage of infection. In cells transfected with the NF-κB-luciferase reporter, infection with LCMV-Arm resulted in the induction of NF-κB, but cells infected with LCMV-WE and CL13 did not. These results suggest that pathogenic arenaviruses suppress NF-κB-mediated proinflammatory cytokine responses in infected cells.Lymphocytic choriomeningitis virus (LCMV), the prototype arenavirus, and Lassa virus (LASV), the causative agent of Lassa fever (LF), have extensive strain diversity and significant variations in pathogenicity for humans and experimental animals. The WE strain of LCMV (LCMV-WE), but not the Armstrong (Arm) strain, induces a fatal LF-like disease in rhesus macaques. We also demonstrated that LASV infection of human macrophages and endothelial cells resulted in reduced levels of proinflammatory cytokines. Here we have shown that cells infected with LASV or with LCMV-WE suppressed Toll-like receptor 2 (TLR2)-dependent proinflammatory cytokine responses. The persisting isolate LCMV clone 13 (CL13) also failed to stimulate interleukin-6 (IL-6) in macrophages. In contrast, nonpathogenic Mopeia virus, which is a genetic relative of LASV and LCMV-Arm induced robust responses that were TLR2/Mal dependent, required virus replication, and were enhanced by CD14. Superinfection experiments demonstrated that the WE strain of LCMV inhibited the Arm-mediated IL-8 response during the early stage of infection. In cells transfected with the NF-κB-luciferase reporter, infection with LCMV-Arm resulted in the induction of NF-κB, but cells infected with LCMV-WE and CL13 did not. These results suggest that pathogenic arenaviruses suppress NF-κB-mediated proinflammatory cytokine responses in infected cells.
Lymphocytic choriomeningitis virus (LCMV), the prototype arenavirus, and Lassa virus (LASV), the causative agent of Lassa fever (LF), have extensive strain diversity and significant variations in pathogenicity for humans and experimental animals. The WE strain of LCMV (LCMV-WE), but not the Armstrong (Arm) strain, induces a fatal LF-like disease in rhesus macaques. We also demonstrated that LASV infection of human macrophages and endothelial cells resulted in reduced levels of proinflammatory cytokines. Here we have shown that cells infected with LASV or with LCMV-WE suppressed Toll-like receptor 2 (TLR2)-dependent proinflammatory cytokine responses. The persisting isolate LCMV clone 13 (CL13) also failed to stimulate interleukin-6 (IL-6) in macrophages. In contrast, nonpathogenic Mopeia virus, which is a genetic relative of LASV and LCMV-Arm induced robust responses that were TLR2/Mal dependent, required virus replication, and were enhanced by CD14. Superinfection experiments demonstrated that the WE strain of LCMV inhibited the Arm-mediated IL-8 response during the early stage of infection. In cells transfected with the NF-κB-luciferase reporter, infection with LCMV-Arm resulted in the induction of NF-κB, but cells infected with LCMV-WE and CL13 did not. These results suggest that pathogenic arenaviruses suppress NF-κB-mediated proinflammatory cytokine responses in infected cells.
Author Salvato, Maria S
Lukashevich, Igor S
Hayes, Melissa W
Carrion, Jr, Ricardo
Medvedev, Andrei E
Nunneley, Jerritt
Author_xml – sequence: 1
  givenname: Melissa W
  surname: Hayes
  fullname: Hayes, Melissa W
  organization: Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA
– sequence: 2
  givenname: Ricardo
  surname: Carrion, Jr
  fullname: Carrion, Jr, Ricardo
– sequence: 3
  givenname: Jerritt
  surname: Nunneley
  fullname: Nunneley, Jerritt
– sequence: 4
  givenname: Andrei E
  surname: Medvedev
  fullname: Medvedev, Andrei E
– sequence: 5
  givenname: Maria S
  surname: Salvato
  fullname: Salvato, Maria S
– sequence: 6
  givenname: Igor S
  surname: Lukashevich
  fullname: Lukashevich, Igor S
BackLink https://www.ncbi.nlm.nih.gov/pubmed/22532679$$D View this record in MEDLINE/PubMed
BookMark eNpNkEtLAzEUhYMo9qE71zJLN9MmaZImSyk-KpWKVF0OedVGZ5KaZAr99w5awc05F853L5czAMc-eAvABYIjhDAfP7zOR5BRyEuEjkAfQcFLShE5_jf3wCClDwgRIYycgh7GdILZVPRB9STzJrxb73SxrE3xFmKnMlovdy62yabC-Y1TLherxTMeP8q6NHZrvbE-F9sYnF_XsmlkDnFf6H0On87_LBU7l2M4AydrWSd7fvAheLm9Wc3uy8Xybj67XpSaTEkuuRVUMU00MRQpaJQVikpsmdFQMsonyqyVUXrSJcoI2eFGKcw5UZTzKcRDcPV7t3vpq7UpV41L2ta19Da0qUIQCYYYFKhDLw9oqxprqm10jYz76q8U_A0XiWdo
CitedBy_id crossref_primary_10_1089_jir_2014_0083
crossref_primary_10_3390_pathogens7040084
crossref_primary_10_3390_v10020075
crossref_primary_10_1371_journal_pone_0122839
crossref_primary_10_1128_JVI_01923_14
crossref_primary_10_1371_journal_pntd_0002171
crossref_primary_10_3389_fimmu_2019_00372
crossref_primary_10_3390_v12070784
crossref_primary_10_1080_14760584_2016_1184575
crossref_primary_10_3390_v4091569
crossref_primary_10_3390_v4112514
crossref_primary_10_3390_v4102182
crossref_primary_10_1074_jbc_M112_375493
crossref_primary_10_3390_v4123625
crossref_primary_10_1089_jir_2012_0140
crossref_primary_10_1586_erv_12_139
crossref_primary_10_3390_v10050232
crossref_primary_10_1128_JVI_00526_15
crossref_primary_10_3390_v16040635
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1128/JVI.06508-11
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Biology
EISSN 1098-5514
ExternalDocumentID 22532679
Genre Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIAID NIH HHS
  grantid: R01 AI068961
– fundername: NIAID NIH HHS
  grantid: R01AI068961
– fundername: NIAID NIH HHS
  grantid: R01AI093450
– fundername: NIAID NIH HHS
  grantid: R01 AI093450
GroupedDBID ---
-~X
.55
.GJ
0R~
18M
29L
2WC
39C
3O-
4.4
41~
53G
5GY
5RE
5VS
6TJ
85S
AAYJJ
ABPPZ
ACGFO
ACNCT
ADBBV
AENEX
AFFNX
AGVNZ
AI.
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BTFSW
C1A
CGR
CS3
CUY
CVF
D0S
DIK
E3Z
EBS
ECM
EIF
EJD
F5P
FRP
GX1
H13
HYE
HZ~
IH2
KQ8
MVM
N9A
NPM
O9-
OHT
OK1
P2P
RHI
RNS
RPM
RSF
TR2
UPT
VH1
W2D
W8F
WH7
WOQ
X7M
Y6R
YQT
ZGI
ZXP
~02
~KM
7X8
AAFWJ
AAGFI
ID FETCH-LOGICAL-c474t-8e95b6c4c4d51b0dbe9b5a2e6dc0a6583bdfbdbc3dbebd9ae95dbb2884b588702
IEDL.DBID 7X8
ISICitedReferencesCount 22
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000305501600019&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1098-5514
IngestDate Fri Sep 05 09:29:04 EDT 2025
Thu Apr 03 07:06:57 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 13
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c474t-8e95b6c4c4d51b0dbe9b5a2e6dc0a6583bdfbdbc3dbebd9ae95dbb2884b588702
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://jvi.asm.org/content/jvi/86/13/7216.full.pdf
PMID 22532679
PQID 1019616091
PQPubID 23479
ParticipantIDs proquest_miscellaneous_1019616091
pubmed_primary_22532679
PublicationCentury 2000
PublicationDate 2012-07-01
PublicationDateYYYYMMDD 2012-07-01
PublicationDate_xml – month: 07
  year: 2012
  text: 2012-07-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Journal of virology
PublicationTitleAlternate J Virol
PublicationYear 2012
References 19052080 - J Virol. 2009 Feb;83(4):1625-34
20360949 - PLoS Pathog. 2010 Mar;6(3):e1000836
20674789 - Infect Genet Evol. 2010 Dec;10(8):1262-70
19801985 - Nat Immunol. 2009 Nov;10(11):1200-7
2462937 - Blood. 1989 Jan;73(1):284-9
9851928 - Science. 1998 Dec 11;282(5396):2079-81
11773391 - J Virol. 2002 Feb;76(3):1154-62
21820469 - Antiviral Res. 2011 Nov;92(2):125-38
9857988 - Virus Genes. 1998;17(2):151-5
22000372 - Emerg Infect Dis. 2011 Oct;17(10):1921-4
15229469 - Nat Rev Immunol. 2004 Jul;4(7):499-511
20616112 - J Leukoc Biol. 2010 Oct;88(4):675-85
12626527 - J Immunol. 2003 Mar 15;170(6):2797-801
11372023 - J Infect Dis. 2001 Jun 15;183(12):1713-21
1840619 - J Virol. 1991 Apr;65(4):1863-9
16254363 - J Virol. 2005 Nov;79(22):14282-96
16723615 - N Engl J Med. 2006 May 25;354(21):2235-49
11992578 - J Med Virol. 2002 Jun;67(2):171-86
17942529 - J Virol. 2008 Jan;82(1):196-206
17409137 - J Virol. 2007 Jun;81(12):6482-90
21880772 - J Virol. 2011 Nov;85(21):11058-68
21632749 - J Virol. 2011 Aug;85(16):8293-306
20725865 - Immunol Res. 2010 Dec;48(1-3):3-13
19019963 - J Virol. 2009 Feb;83(3):1492-500
21185048 - Virology. 2011 Mar 15;411(2):170-9
18036672 - Antiviral Res. 2008 Apr;78(1):79-90
14990737 - J Virol. 2004 Mar;78(6):3162-9
15724245 - Eur J Immunol. 2005 Mar;35(3):822-30
18931067 - J Gen Virol. 2008 Nov;89(Pt 11):2713-22
19478873 - PLoS Pathog. 2009 May;5(5):e1000455
16621649 - Microbes Infect. 2006 Apr;8(5):1194-202
11987809 - Curr Top Microbiol Immunol. 2002;262:75-109
17804508 - J Virol. 2007 Nov;81(22):12696-703
21572983 - PLoS Negl Trop Dis. 2011;5(5):e1137
1585636 - Virology. 1992 Jun;188(2):600-5
20592086 - J Virol. 2010 Sep;84(18):9452-62
14978087 - J Immunol. 2004 Mar 1;172(5):2861-9
3940312 - N Engl J Med. 1986 Jan 2;314(1):20-6
1316111 - Arch Pathol Lab Med. 1992 May;116(5):486-8
21548931 - Virol J. 2011;8:205
12525606 - J Virol. 2003 Feb;77(3):1727-37
18272355 - Curr Opin Immunol. 2008 Feb;20(1):17-22
21880754 - J Virol. 2011 Nov;85(22):12093-7
22156524 - J Virol. 2012 Feb;86(4):2067-78
19255625 - PLoS Negl Trop Dis. 2009;3(3):e388
18650788 - MMWR Morb Mortal Wkly Rep. 2008 Jul 25;57(29):799-801
11905821 - Nat Rev Immunol. 2001 Nov;1(2):135-45
19324387 - Virology. 2009 May 10;387(2):245-9
19297492 - J Virol. 2009 Jun;83(11):5890-903
18292534 - J Immunol. 2008 Mar 1;180(5):3113-21
15338320 - Arch Virol. 2004 Dec;149(12):2319-36
21098292 - Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21641-6
18625310 - Curr Opin Immunol. 2008 Aug;20(4):420-5
18052527 - PLoS Pathog. 2007 Nov;3(11):e149
2389568 - Vopr Virusol. 1990 Mar-Apr;35(2):146-50
10534741 - J Med Virol. 1999 Dec;59(4):552-60
15577929 - Nat Med. 2004 Dec;10(12 Suppl):S110-21
22238311 - J Virol. 2012 Mar;86(6):3389-92
21270335 - Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):2969-74
16940530 - J Virol. 2006 Sep;80(18):9192-9
17557350 - Ann Neurol. 2007 Oct;62(4):347-55
17522210 - J Virol. 2007 Aug;81(15):7960-73
21171877 - Expert Rev Anti Infect Ther. 2011 Jan;9(1):49-59
References_xml – reference: 16621649 - Microbes Infect. 2006 Apr;8(5):1194-202
– reference: 9851928 - Science. 1998 Dec 11;282(5396):2079-81
– reference: 15577929 - Nat Med. 2004 Dec;10(12 Suppl):S110-21
– reference: 10534741 - J Med Virol. 1999 Dec;59(4):552-60
– reference: 22156524 - J Virol. 2012 Feb;86(4):2067-78
– reference: 11773391 - J Virol. 2002 Feb;76(3):1154-62
– reference: 16254363 - J Virol. 2005 Nov;79(22):14282-96
– reference: 16723615 - N Engl J Med. 2006 May 25;354(21):2235-49
– reference: 1585636 - Virology. 1992 Jun;188(2):600-5
– reference: 18292534 - J Immunol. 2008 Mar 1;180(5):3113-21
– reference: 11992578 - J Med Virol. 2002 Jun;67(2):171-86
– reference: 9857988 - Virus Genes. 1998;17(2):151-5
– reference: 14990737 - J Virol. 2004 Mar;78(6):3162-9
– reference: 1840619 - J Virol. 1991 Apr;65(4):1863-9
– reference: 14978087 - J Immunol. 2004 Mar 1;172(5):2861-9
– reference: 21185048 - Virology. 2011 Mar 15;411(2):170-9
– reference: 21632749 - J Virol. 2011 Aug;85(16):8293-306
– reference: 1316111 - Arch Pathol Lab Med. 1992 May;116(5):486-8
– reference: 19478873 - PLoS Pathog. 2009 May;5(5):e1000455
– reference: 22238311 - J Virol. 2012 Mar;86(6):3389-92
– reference: 15724245 - Eur J Immunol. 2005 Mar;35(3):822-30
– reference: 19801985 - Nat Immunol. 2009 Nov;10(11):1200-7
– reference: 21880772 - J Virol. 2011 Nov;85(21):11058-68
– reference: 19324387 - Virology. 2009 May 10;387(2):245-9
– reference: 20360949 - PLoS Pathog. 2010 Mar;6(3):e1000836
– reference: 21548931 - Virol J. 2011;8:205
– reference: 19019963 - J Virol. 2009 Feb;83(3):1492-500
– reference: 15229469 - Nat Rev Immunol. 2004 Jul;4(7):499-511
– reference: 2462937 - Blood. 1989 Jan;73(1):284-9
– reference: 18931067 - J Gen Virol. 2008 Nov;89(Pt 11):2713-22
– reference: 21270335 - Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):2969-74
– reference: 21572983 - PLoS Negl Trop Dis. 2011;5(5):e1137
– reference: 17804508 - J Virol. 2007 Nov;81(22):12696-703
– reference: 21820469 - Antiviral Res. 2011 Nov;92(2):125-38
– reference: 22000372 - Emerg Infect Dis. 2011 Oct;17(10):1921-4
– reference: 19297492 - J Virol. 2009 Jun;83(11):5890-903
– reference: 20674789 - Infect Genet Evol. 2010 Dec;10(8):1262-70
– reference: 12525606 - J Virol. 2003 Feb;77(3):1727-37
– reference: 16940530 - J Virol. 2006 Sep;80(18):9192-9
– reference: 18272355 - Curr Opin Immunol. 2008 Feb;20(1):17-22
– reference: 18650788 - MMWR Morb Mortal Wkly Rep. 2008 Jul 25;57(29):799-801
– reference: 18625310 - Curr Opin Immunol. 2008 Aug;20(4):420-5
– reference: 17557350 - Ann Neurol. 2007 Oct;62(4):347-55
– reference: 11905821 - Nat Rev Immunol. 2001 Nov;1(2):135-45
– reference: 12626527 - J Immunol. 2003 Mar 15;170(6):2797-801
– reference: 19052080 - J Virol. 2009 Feb;83(4):1625-34
– reference: 11372023 - J Infect Dis. 2001 Jun 15;183(12):1713-21
– reference: 2389568 - Vopr Virusol. 1990 Mar-Apr;35(2):146-50
– reference: 19255625 - PLoS Negl Trop Dis. 2009;3(3):e388
– reference: 21880754 - J Virol. 2011 Nov;85(22):12093-7
– reference: 17522210 - J Virol. 2007 Aug;81(15):7960-73
– reference: 18036672 - Antiviral Res. 2008 Apr;78(1):79-90
– reference: 3940312 - N Engl J Med. 1986 Jan 2;314(1):20-6
– reference: 20725865 - Immunol Res. 2010 Dec;48(1-3):3-13
– reference: 21171877 - Expert Rev Anti Infect Ther. 2011 Jan;9(1):49-59
– reference: 18052527 - PLoS Pathog. 2007 Nov;3(11):e149
– reference: 11987809 - Curr Top Microbiol Immunol. 2002;262:75-109
– reference: 20616112 - J Leukoc Biol. 2010 Oct;88(4):675-85
– reference: 20592086 - J Virol. 2010 Sep;84(18):9452-62
– reference: 17409137 - J Virol. 2007 Jun;81(12):6482-90
– reference: 17942529 - J Virol. 2008 Jan;82(1):196-206
– reference: 21098292 - Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21641-6
– reference: 15338320 - Arch Virol. 2004 Dec;149(12):2319-36
SSID ssj0014464
Score 2.173375
Snippet Lymphocytic choriomeningitis virus (LCMV), the prototype arenavirus, and Lassa virus (LASV), the causative agent of Lassa fever (LF), have extensive strain...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 7216
SubjectTerms Animals
Cell Line
Cytokines - antagonists & inhibitors
Humans
Immune Evasion
Lassa virus - immunology
Lassa virus - pathogenicity
Lymphocytic choriomeningitis virus - immunology
Lymphocytic choriomeningitis virus - pathogenicity
Membrane Transport Proteins - immunology
Mice
Mice, Inbred C57BL
Mice, Knockout
Myelin and Lymphocyte-Associated Proteolipid Proteins
Myelin Proteins - antagonists & inhibitors
Myelin Proteins - immunology
NF-kappa B - antagonists & inhibitors
NF-kappa B - immunology
Proteolipids - antagonists & inhibitors
Proteolipids - immunology
Toll-Like Receptor 2 - antagonists & inhibitors
Toll-Like Receptor 2 - immunology
Title Pathogenic Old World arenaviruses inhibit TLR2/Mal-dependent proinflammatory cytokines in vitro
URI https://www.ncbi.nlm.nih.gov/pubmed/22532679
https://www.proquest.com/docview/1019616091
Volume 86
WOSCitedRecordID wos000305501600019&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8NAFB7UKnhxX-rGCF7HZplsJxGxqNhapEpvIbNhsCa1SQv9976ZJPQkCF5yCQPDyzfvfZm3fAhdJS4ERS-iRFpKt-T4PomkpMR3HHNtQaWvjNhE0O-Ho1E0qC_cirqssvGJxlGLnOs7cjjdgBXbh_B2M_kmWjVKZ1drCY1V1HKBymhUB6NlFgF-dUxWWc_M1MygKXx3ws7T--O1YSfEtn8nlybIdLf_u70dtFXTS3xb4WEXrchsD21UgpOLfRQPgPDlgJmU45exwKaUBut-sGSeTmeFLHCafaQsLfHw-dXp9JIxaWRySwxbAjwChL5Mah7zRZl_6rJ5WITnaTnND9Bb935490BqiQXCaUBLEsrIYz6nnArPZpZgMmJe4khfcCsBcuIyoZhg3IU3TOhB3p5gzAlDyjxwT5ZziNayPJPHCAsFX1sFCQNGR4WKEsuSusdLubaKmO-20WVjuRggrPMSSSbzWREvbddGR5X540k1ayMGdwMEM4hO_rD6FG0CnamLac9QS8EBludonc_LtJheGGzAsz_o_QBVtMXT
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pathogenic+Old+World+arenaviruses+inhibit+TLR2%2FMal-dependent+proinflammatory+cytokines+in+vitro&rft.jtitle=Journal+of+virology&rft.au=Hayes%2C+Melissa+W&rft.au=Carrion%2C+Ricardo&rft.au=Nunneley%2C+Jerritt&rft.au=Medvedev%2C+Andrei+E&rft.date=2012-07-01&rft.issn=1098-5514&rft.eissn=1098-5514&rft.volume=86&rft.issue=13&rft.spage=7216&rft_id=info:doi/10.1128%2FJVI.06508-11&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1098-5514&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1098-5514&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1098-5514&client=summon